Wang et al developed models for evaluating a patient with an osteosarcoma of an extremity. This can help to identify a patient who may benefit from more aggressive management. The authors are from First Affilitated Hospital of Sun Yat-Sen University in Guangdong, China.
Patient selection: extremity osteosarcoma, Enneking stage II or III (not I), presumably all Chinese
Outcome: overall 5-year survival
Pretreatment parameters:
(1) Enneking stage
(2) tumor diameter in centimeters
(3) age in years and serum alkaline phosphatase in IU/L (method not specified)
(4) absolute neutrophil count in 10^9/L
(5) platelet count in 10^9/L
|
Parameter |
Finding |
Points |
|
Enneking stage |
IIA |
0 |
|
|
IIB |
2 |
|
|
III |
4 |
|
tumor diameter |
<= 8 cm |
0 |
|
|
> 8 cm |
1 |
|
age and ALP |
< 18 and ALP < 150 |
0 |
|
|
< 18 and ALP >= 150 |
3 |
|
|
>= 18 and ALP < 110 |
0 |
|
|
>= 18 and ALP >= 110 |
3 |
|
neutrophil count in 10^9 |
< 6.4 |
0 |
|
|
>= 6.4 |
1 |
|
platelet count in 10^9 |
< 300 |
0 |
|
|
>= 300 |
1 |
total score =
= SUM(points for all 5 parameters)
Interpretation:
• minimum score: 0
• maximum score: 10
• The higher the score the worse the overall 5-year survival.
|
Total Score |
Risk Group |
5 Year Overall Survival |
|
0 to 3 |
low |
96% |
|
4 to 6 |
intermediate |
70% |
|
7 to 10 |
high |
36% |
Performance:
• The area under the ROC curve was 0.72 (training set) and 0.71 (validation set).
Specialty: Hematology Oncology, Surgery, general, Surgery, orthopedic
